After obtaining a Master’s degree in Life Sciences from the “École Pratique des Hautes Études” (Paris Sciences and Letters University) in 2022, Marina Villaverde has just started a PhD thesis. Through the collaboration between the Institute for Regenerative Medicine and Biotherapies and HCS Pharma, this PhD work will focus on the development of a new osteoarthritic model in vitro with the 3D BIOMIMESYS® technology in order to identify new therapies for this common and so far uncured disease.
Last week HCS Pharma was pleased to take part to Elrig Uk Research & Innovation. This event took place on the 20 and 21 March in Manchester. It was a great opportunity to share another Read more…
The annual “Research and Innovation” congress by ELRIG UK will take place on 20 and 21 March in Manchester. We are delighted to participate in this event with a poster presentation and a booth in Read more…
RIKEN, equivalent to CNRS in France, is a national research and development agency based in Japan and is the largest comprehensive research institution in the country. After RIKEN symposium held in Belgium on February 14 Read more…
0 Comments